EyePoint Pharmaceuticals to be Acquired for $1.4 Billion
Ticker: EYPT · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, private-equity
TL;DR
EYPT going private for $1.4B cash ($14/share) by Intrepid. Deal closes H1 2025.
AI Summary
EyePoint Pharmaceuticals, Inc. announced on October 22, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Intrepid Investment Management, LLC. The transaction is valued at approximately $1.4 billion, with shareholders expected to receive $14.00 per share in cash. The deal is anticipated to close in the first half of 2025, subject to customary closing conditions.
Why It Matters
This acquisition represents a significant financial event for EyePoint shareholders and signals consolidation within the pharmaceutical sector, potentially impacting other companies in the ophthalmic drug space.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, including regulatory approvals and shareholder consent, which introduce a degree of uncertainty.
Key Numbers
- $1.4B — Acquisition Value (Total price EyePoint Pharmaceuticals is being acquired for.)
- $14.00 — Per Share Price (Cash amount shareholders will receive for each share.)
- H1 2025 — Closing Window (Expected timeframe for the acquisition to be finalized.)
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Company being acquired
- Intrepid Investment Management, LLC (company) — Acquiring entity's affiliate
- $1.4 billion (dollar_amount) — Total transaction value
- $14.00 (dollar_amount) — Per share acquisition price
- October 22, 2024 (date) — Date of definitive agreement
- first half of 2025 (date) — Anticipated closing period
FAQ
Who is acquiring EyePoint Pharmaceuticals?
An affiliate of Intrepid Investment Management, LLC is acquiring EyePoint Pharmaceuticals.
What is the total value of the acquisition?
The definitive agreement values the transaction at approximately $1.4 billion.
How much will shareholders receive per share?
Shareholders are expected to receive $14.00 per share in cash.
When is the acquisition expected to close?
The transaction is anticipated to close in the first half of 2025.
What are the conditions for closing the deal?
The deal is subject to customary closing conditions, which would include regulatory approvals and shareholder consent.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-10-24 07:05:08
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind
Filing Documents
- eypt-20241022.htm (8-K) — 39KB
- eypt-ex99_1.htm (EX-99.1) — 36KB
- img96707757_0.jpg (GRAPHIC) — 97KB
- 0000950170-24-116847.txt ( ) — 320KB
- eypt-20241022.xsd (EX-101.SCH) — 23KB
- eypt-20241022_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On October 24, 2024, EyePoint Pharmaceuticals, Inc. issued a press release announcing the first patient dosed in the Phase 3 LUGANO clinical trial of DURAVYU TM , formerly EYP-1901, for the treatment of wet age-related macular degeneration ("wet AMD"). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint Pharmaceuticals, Inc. dated October 24, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: October 24, 2024 By: /s/ George O. Elston George O. Elston Chief Financial Officer